share_log

Arcutis Biotherapeutics | 144: Notice of proposed sale of securities pursuant to Rule 144

Arcutis Biotherapeutics | 144：擬議出售證券

SEC announcement ·  03/04 17:47
Moomoo AI 已提取核心訊息
Arcutis Biotherapeutics, Inc. officer Matthew Richard Moore is set to sell 3,468 shares of common stock on March 4, 2024. The shares, valued at an aggregate market value of $38,568, were acquired on March 1, 2024, through a restricted stock vest from Arcutis Biotherapeutics. This transaction follows a period where no securities were sold by Moore in the past three months, as per the latest filings.
Arcutis Biotherapeutics, Inc. officer Matthew Richard Moore is set to sell 3,468 shares of common stock on March 4, 2024. The shares, valued at an aggregate market value of $38,568, were acquired on March 1, 2024, through a restricted stock vest from Arcutis Biotherapeutics. This transaction follows a period where no securities were sold by Moore in the past three months, as per the latest filings.
Arcutis Biotherapeutics, Inc.高管馬修·理查德·摩爾定於2024年3月4日出售3,468股普通股。這些股票的總市值爲38,568美元，於2024年3月1日通過Arcutis Biotherapeutics的限制性股票背心收購。根據最新文件，這筆交易是在摩爾在過去三個月中沒有出售任何證券的時期之後進行的。
Arcutis Biotherapeutics, Inc.高管馬修·理查德·摩爾定於2024年3月4日出售3,468股普通股。這些股票的總市值爲38,568美元，於2024年3月1日通過Arcutis Biotherapeutics的限制性股票背心收購。根據最新文件，這筆交易是在摩爾在過去三個月中沒有出售任何證券的時期之後進行的。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息